Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Income from Continuing Operations: 2017-2019

Historic Income from Continuing Operations for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' Income from Continuing Operations fell 32.23% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 36.88%. This contributed to the annual value of -$4.3 million for FY2019, which is 31.04% down from last year.
  • As of Q4 2019, Monopar Therapeutics' Income from Continuing Operations stood at -$1.2 million, which was down 61.29% from -$759,448 recorded in Q3 2019.
  • Monopar Therapeutics' 5-year Income from Continuing Operations high stood at -$373,839 for Q1 2017, and its period low was -$14.9 million during Q3 2017.
  • Its 3-year average for Income from Continuing Operations is -$2.0 million, with a median of -$828,354 in 2018.
  • The largest annual percentage gain for Monopar Therapeutics' Income from Continuing Operations in the last 5 years was 95.52% (2018), contrasted with its biggest fall of 140.01% (2018).
  • Quarterly analysis of 3 years shows Monopar Therapeutics' Income from Continuing Operations stood at -$736,800 in 2017, then declined by 25.73% to -$926,358 in 2018, then slumped by 32.23% to -$1.2 million in 2019.
  • Its Income from Continuing Operations stands at -$1.2 million for Q4 2019, versus -$759,448 for Q3 2019 and -$932,109 for Q2 2019.